Biovica International AB (publ), listed on Nasdaq First North Premier Growth Market, has carried out a fully guaranteed preferential rights issue of shares for existing shareholders corresponding to approximately SEK 148 million.
Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica’s assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer.
Van Lanschot Kempen and Pareto Securities acted as Joint Bookrunners. Baker McKenzie acted as legal advisor to Biovica with a capital markets team e.g. consisting of Stefan Balazs, Joakim Falkner, Johanna Flink, Oscar Bang, Elsa Antonsson and Carl Isaksson.